Dapagliflozin/saxagliptin

Drug Profile

Dapagliflozin/saxagliptin

Alternative Names: Qtern; Saxa/dapa; SaxaDapa; SaxaDapa FDC; Saxagliptin/dapagliflozin

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; Bristol-Myers Squibb; University of Texas Health Science Center at San Antonio
  • Class Adamantanes; Antihyperglycaemics; Chlorobenzenes; Cycloparaffins; Dipeptides; Glucosides; Nitriles; Organic bridged compounds; Piperidines; Pyrans; Small molecules
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 06 Feb 2017 Launched for Type-2 diabetes mellitus in European Union (PO) before February 2017 (AstraZeneca pipeline, February 2017)
  • 01 Sep 2016 Bristol-Myers Squibb and AstraZeneca complete a phase IIIb trial for Type-2 diabetes mellitus (Combination therapy) in USA, Mexico, South Africa, Poland, Hungary and Romania (NCT02284893)
  • 19 Jul 2016 Registered for Type-2 diabetes mellitus in Liechtenstein, Iceland, Norway, European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top